Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-05-06 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于子公司药品生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a change in the production license of its subsidiary. It details the change of production address for a pharmaceutical product and the impact of this change on the company. The document is short (1024 characters) and does not contain financial statements or detailed financial data. It is an announcement about a regulatory approval and operational change rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-06 Chinese
独立董事关于第四届董事会第十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to a board meeting agenda item about increasing the estimated amount of related party transactions for the year 2022. It references compliance with company law, securities law, stock exchange listing rules, and internal company regulations. The content focuses on governance and regulatory compliance regarding related party transactions and board meeting procedures. It does not contain financial statements, audit results, earnings data, or detailed financial analysis. It is not a report or announcement of financial results but rather a governance-related document expressing independent directors' opinions on a board matter. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements related to board activities and management decisions.
2022-05-06 Chinese
独立董事关于第四届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding matters discussed at the 12th meeting of the 4th board of directors. It includes opinions on related party transactions and the resignation and nomination of independent directors. The content focuses on board/management matters, specifically changes in board composition and governance procedures. There is no financial data, earnings information, or report publication announcement. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's board and related governance opinions.
2022-05-06 Chinese
关于召开2022年第三次临时股东大会通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice for convening the 2022 third extraordinary general meeting of shareholders of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes information about the meeting date, time, venue, agenda items, voting procedures (including online voting), registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and agenda, not on reporting financial results or management discussions. There is no financial data or analysis presented, nor is it a transcript or announcement of voting results. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2022-05-05 Chinese
关于拟变更公司独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's independent directors, including a resignation and a proposed new appointment. It details the resignation of an independent director and the nomination of a new candidate, along with relevant qualifications and approvals. There is no financial data, earnings information, or report publication mentioned. The content fits the category of announcements about changes in the company's board of directors or senior management.
2022-05-05 Chinese
关于追加公司及子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' application for an increased comprehensive credit limit from banks. It details board meeting approvals and the impact of this financing activity on the company. There are no financial statements or detailed financial performance data included. The document focuses on capital structure and financing updates, specifically about credit facilities. The document length is short (874 characters), but it contains substantive information about financing activities, not just a notice of report publication. Therefore, it fits best under Capital/Financing Update (CAP).
2022-05-05 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.